Insulin aspart protamine and insulin aspart - Biologic Drug Details

Summary for insulin aspart protamine and insulin aspart

Tradenames:	2
High Confidence Patents:	13
Applicants:	1
BLAs:	2
Suppliers: see list	4

Pharmacology for insulin aspart protamine and insulin aspart

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin aspart protamine and insulin aspart Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin aspart protamine and insulin aspart Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLOG MIX 70/30	insulin aspart protamine and insulin aspart	Injectable Suspension	021172		2013-09-28	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 70/30	insulin aspart protamine and insulin aspart	Injectable Suspension	021172		2006-08-29	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 70/30	insulin aspart protamine and insulin aspart	Injectable Suspension	021172		2014-09-26	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 70/30	insulin aspart protamine and insulin aspart	Injectable Suspension	021172		2016-12-11	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 70/30	insulin aspart protamine and insulin aspart	Injectable Suspension	021172		2016-12-11	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 70/30	insulin aspart protamine and insulin aspart	Injectable Suspension	021172		2017-06-20	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLOG MIX 70/30	insulin aspart protamine and insulin aspart	Injectable Suspension	021172		2017-06-19	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin aspart protamine and insulin aspart Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for insulin aspart protamine and insulin aspart

Country	Patent Number	Estimated Expiration
Austria	E452669
World Intellectual Property Organization (WIPO)	2006079481
Spain	2001624
Greece	3015031
Russian Federation	2254878
Canada	2584762
New Zealand	217406

Supplementary Protection Certificates for insulin aspart protamine and insulin aspart

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB00/027	United Kingdom		PRODUCT NAME: INSULIN ASPART AND PROTAMINE (NOVOMIX 30); REGISTERED: CH 55414 01 20000623; CH 55415 02 20000623; CH 55416 02 20000623; UK EU/1/00/142/001-008 20000801
C990042	Netherlands		PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
10199011	Germany		PRODUCT NAME: KRISTALLE, ENTHALTEND ASP B28 HUMAN-INSULIN UND PROTAMIN; REGISTRATION NO/DATE: EU/1/00/142/001-008 20000801
SPC/GB99/045	United Kingdom		SPC/GB99/045: 20060829, EXPIRES: 20110828
SZ 50/1999	Austria		PRODUCT NAME: INSULIN ASPART
CA 2005 00047	Denmark		PRODUCT NAME: INSULIN ASPART, PROTAMINKRYSTALLISERET
99C0044	Belgium		PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615

Market Dynamics and Financial Trajectory for Insulin Aspart Protamine and Insulin Aspart

Last updated: December 23, 2025

Summary

Insulin aspart protamine (commonly branded as Fiasp or similar formulations with added protamine) and insulin aspart represent critical advances in basal-bolus insulin therapy, especially for individuals with diabetes mellitus. Their market trajectory is shaped by evolving clinical data, regulatory landscapes, patent life cycles, and payer strategies amid the global diabetes epidemic. This assessment delineates current market dynamics, projected financial growth, competitive landscapes, and strategic considerations connecting these insulin analogs’ future profitability.

---

What Are Insulin Aspart and Insulin Aspart Protamine?

Component	Description	Brand Examples	Regulatory Status
Insulin Aspart	Rapid-acting insulin analogue with an onset of action within 10-20 minutes	NovoRapid (Novo Nordisk), Fiasp (Novo Nordisk)	Approved globally; Fiasp approved by FDA (2017) and EMA (2018)
Insulin Aspart Protamine	Extended-acting formulation (once-daily or basal-bolus regimens) combining insulin aspart with protamine	Fiasp (with modifications), Biocon's biosimilars	Pending biosimilar approvals; patent expiries ongoing

Key Differentiator: Incorporating protamine prolongs insulin action, enabling basal or premixed formulations, offering more flexible regimens.

---

Market Drivers

Global Diabetes epidemic

• Prevalence: Nearly 537 million adults affected globally in 2021; projected to reach 643 million by 2030 [[1]].
• Type 1 and Type 2 diabetes: Both populations require insulin therapies, expanding the market scope.
• Fit with current treatment paradigms: Rapid-acting insulins are critical for meal-time glucose management; basal insulins support fasting glucose control.

Technological Advancements

• Ultra-rapid formulations: Fiasp’s faster onset (within 10 minutes) offers clinical advantages over traditional insulin aspart.
• Delivery Devices: Pen injectors and insulin pump integration drive increased adoption.

Regulatory and Reimbursement Landscape

• FDA and EMA approvals for Fiasp bolster market penetration.
• Payer acceptance increasingly favors fast-acting insulins due to improved glycemic outcomes, influencing formulary placements.

---

Market Dynamics

Competitive Landscape

Players	Key Products	Market Share (2022)	Strategic Moves
Novo Nordisk	NovoRapid, Fiasp	~50%	Innovation pipeline, biosimilars, global expansion
Eli Lilly	Admelog, Basaglar	~20%	Biosimilar developments, marketing strategies
Biocon / Mylan	Biosimilar insulin aspart	Emerging	Cost-sensitive Markets, biosimilar launches
Sanofi	Insulin Lispro, biosimilars	Remaining share	Diversification, biosimilar pipeline

Patent Expiry and Biosimilar Competition

• The original NovoRapid patent expired in 2013 in the US, with Fiasp's patent expiring in the late 2020s.
• Biosimilar insulin aspart products are entering key markets, reducing prices and pressuring margins.

Pricing Trends

• Premium Pricing: Fiasp commands a premium (~10-20%) over traditional insulin aspart, justified by faster action.
• Price erosion: Biosimilars are expected to decrease insulin aspart prices by 25-50% over the next 5 years, impacting revenue streams.

Market Penetration and Adoption Factors

• Clinical Efficacy: Demonstrated benefits in reducing postprandial glucose spikes.
• Patient Preference: Ease of use, rapid onset, and reduced hypoglycemia risk influence prescribing trends.
• Formulation Improvements: Future innovations include concentrated and inhaled insulins.

---

Financial Trajectory: Revenue, Growth, and Investment

Historical Revenue Estimates (2020-2022)

Year	Estimated Revenue (US$ billion)	Growth Rate	Remarks
2020	4.2	—	Major contributor: Novo Nordisk
2021	4.9	+16.7%	Launch of Fiasp; increased adoption
2022	5.5	+12.2%	Market expansion; biosimilar entries anticipated

Forecasted Trends (2023-2027)

Year	Predicted Revenue (US$ billion)	Compound Annual Growth Rate (CAGR)	Drivers
2023	6.1	+10.9%	Stronger biosimilar competition, geographic expansion
2024	6.7	+9.8%	Increased patient compliance, technological integration
2025	7.5	+11.9%	Emerging markets penetration, new formulations
2026	8.2	+9.3%	Patent expiration effects, price erosion
2027	8.8	+7.3%	Market stabilization, lifecycle management

Note: The projections incorporate market expansion, biosimilar pricing impacts, and regulatory approvals.

Profitability and Cost Considerations

Cost Components	Estimated Impact Per Unit ($)	Implications	Mitigation Strategies
R&D	10-15	High investment for innovation	Collaborations, in-licensing
Manufacturing	1-2	Economies of scale reduce costs	Automation, biosimilar manufacturing
Marketing & Distribution	3-5	Competitive positioning	Digital channels, direct-to-consumer models

---

Comparison with Alternative Insulin Therapies

Parameter	Insulin Aspart / Protamine	Regular Insulin	Insulin Glargine	Inhaled Insulin
Onset of Action	10-20 min	30-60 min	1 hour	12-15 min
Duration	3-5 hours	6-8 hours	Up to 24 hours	2-3 hours
Efficacy	High for meal control	Moderate	Long-acting basal control	Quick peak, basal equivalent
Market Share	Growing	Declining	Steady	Niche segment

---

Regulatory and Policy Impacts

• Label updates and clinical guidelines (e.g., ADA/EASD recommendations) favor rapid-acting insulins.
• Policies promoting biosimilar adoption in the US, EU, and emerging markets influence pricing strategies.
• Reimbursement policies increasingly favor insulin analogs with superior outcomes, impacting payer decisions.

---

Future Outlook: Innovation and Market Opportunities

Opportunity Area	Description	Status	Impact
Biosimilar Insulin Aspart	Cost-effective alternatives	Approaching approval	Market share redistribution
Ultra-rapid formulations	Faster onset for improved glycemic control	Clinical trials ongoing	Premium pricing potential
Smart Delivery Devices	Integration with digital health tools	Emerging	Enhances adherence and market loyalty
Regional Expansion	Growing markets in Asia, Africa	Market entry strategies underway	Revenue diversification

---

Key Takeaways

• Market Expansion: The global diabetes prevalence boom underpins sustained growth for insulin aspart and insulin aspart protamine analogs.
• Pricing and Competition: Biosimilar entries threaten to erode profit margins; innovation in formulations and delivery systems remain vital.
• Revenue Trajectory: Industry forecasts predict a CAGR of approximately 9-11% over the next five years, supported by clinical benefits and expanded access.
• Regulatory Environment: Advances facilitated by approvals, alongside policies promoting biosimilars, will shape competitive strategies.
• Strategic Focus: Companies focusing on innovation, geographic expansion, and digital health integration are poised to capitalize on market growth.

---

Frequently Asked Questions

1. What are the primary clinical advantages of insulin aspart protamine over traditional insulins?

Insulin aspart protamine provides rapid onset (around 10-20 minutes), closely mimicking physiological post-meal insulin response. When combined with protamine, it extends duration, enabling basal coverage and reducing hypoglycemia risk compared to conventional intermediate-acting insulins.

2. How does the patent landscape influence the growth prospects of insulin aspart formulations?

Original patents for NovoRapid have expired or are expiring, paving the way for biosimilar competitors, which exert downward pressure on pricing. However, formulations like Fiasp benefit from extended patent protections until late 2020s/2030s, allowing premium pricing and market differentiation.

3. Which regions present the most significant growth opportunities for these insulins?

Emerging markets in Asia, Africa, and Latin America hold substantial potential due to increasing diabetes prevalence, rising healthcare expenditure, and evolving reimbursement policies. Regulatory harmonization and local manufacturing also facilitate market entry and expansion.

4. What role do technological innovations play in the future trajectory of insulin aspart products?

Advances such as ultra-rapid formulations, smart injectors, and integrated digital health solutions improve patient compliance, glycemic control, and market differentiation, potentially commanding premium pricing and loyalty.

5. What challenges do manufacturers face in maintaining profitability amidst biosimilar competition?

Price erosion, payer pressure, and regulatory hurdles challenge profitability. Investing in innovation and value-added delivery solutions, alongside strategic regional expansion, are essential to mitigate these risks.

---

References

[1] International Diabetes Federation. (2021). IDF Diabetes Atlas, 9th Edition.
[2] US Food and Drug Administration. (2017). Fiasp approval memo.
[3] European Medicines Agency. (2018). Fiasp marketing authorization.
[4] IQVIA. (2022). Global Insulin Market Data.
[5] Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report.

---